Articles On Amplia Therapeutics (ASX:ATX)

ASX retreats from early rally to add just 0.16% Traders react with scepticism to Trump’s Iranian assurances Materials sector snaps four-day losing streak, still down -20.2% from highs   Markets go hungry It seems the S&P/ASX 200 was l...

A UBS analysis shows that healthcare stocks accounted for five of the top 20 blue chip outperformers during previous market meltdowns Radiopharm’s brain ‘mets’ imaging trial continues to hit primary endpoints Cyclopharm shares surge on US...

Highlights Energy and mining stocks dominate current momentum trends Select companies show sustained upward price strength Market rotation signals renewed sectoral interest Energy and mining sectors are shaping ASX momentum trends...

Highlights Energy and mining stocks drive strong upward momentum Select sectors face persistent downward pressure Trend-based scanning reveals shifting market leadership Australian market trends reveal strong momentum in energy an...

Amplia Therapeutics Ltd (ASX: ATX) shares certainly had a day to remember on Monday. When many ASX shares were tumbling with the market, this small-cap stock doubled in value to 23.5 cents. The catalyst for this was the release of updated d...

ASX recovers from session lows of -1.97%, falling -0.74% Five sectors – materials, info tech, health, real estate and discretionary – enter bear market territory Defensive sectors climb despite broader losses   Five ASX sectors turn beari...

Greetings and welcome to HotCopper’s The ASX Today for Monday, Week 13, I’m Isaac McIntyre – replacing Jonathon Davidson all through this week as he enjoys a few days back home in sunny Darwin, and what a week it could be as I temporarily p...

Pancreatic cancer is normally a death sentence, but five patients in Amplia’s studies have emerged tumour free It’s a case of ‘good golly Molly’ as medical pot platform joins the psychedelics push Nexsen wins positive FDA feedback on its p...

ASX update – Week 12 has opened with another brutal drop, though the -1.6% landslide we were staring down when I was recording the Market Open this morning has subsided a little to lunchtime. That said, things are still very much in the red...

Morning, and welcome to Stockhead’s Top 10 (at 11… ish), highlighting the movers and shakers on the ASX in early-doors trading. With the market opening at 10am sharp eastern time, the data is taken at 10.15am in the east, once trading kicks...

ASX plunges 1.65%, erasing the week’s gains and then some Hard hits in gold stocks, but broad pullback with eight sectors lower Energy stocks catch a tailwind as crude prices spike   Oil surges as Iran hits Qatar’s LNG operations again Qa...

Telix shares surge as much as 14% after its most advanced cancer therapy candidate passes phase III safety and dosimetry hurdles Clarity says it will achieve the targeted 220 patients for its prostate cancer imaging trial Illinois expansio...

ASX healthcare sector falls 13.31% in February as benchmark ASX 200 up 4% Blood products and vaccines giant CSL weighed heavily on sector down 19.1% in February Rhythm Biosciences up 48% in February to be sector’s biggest gainer for the mo...

ASX healthcare sector rises 2.25% in January as benchmark ASX 200 up 1.78% Index largely supported by the sector’s largest stock CSL, up 5.1% in January Anteris and PYC announce monster capital raises with strong support from US investors...

ASX shook off an early wobble to finish the first trading day of 2026 up 0.15% Energy, uranium and banks lead while gold stocks slip Northern Star slumps on guidance cuts as Nickel Industries surges on strategic deal   The ASX opened on...

ASX healthcare sector gains 1.99% in November while benchmark ASX 200 down 2.66% Mach7 rises 50% in November with health imaging stock outlining a growth strategy at its AGM  Island Pharmaceuticals rises after FDA confirms Galidesivir will...

ASX shrugs off hot CPI read, closes up 0.81% Gold, lithium, rare earths lead resources gains Broad upward momentum across eight sectors   Gold and lithium build momentum Lion Selection Group (ASX:LSX) MD Hedley Widdup predicted Australia...

ASX healthcare sector fell 4.83% in October and is down more than 19% YTD CSL shares fall more than 15% on October 28 after management trims FY26 guidance Nyrada surges 165% in October on board changes and progress in phase 2a trial    Wi...

Highlights Artrya (ASX:AYA) expands with major funding for heart disease detection devices Telix Pharmaceuticals (ASX:TLX) advances brain cancer imaging with FDA alignment Argenica Therapeutics (ASX:AGN) gains traction with...

The S&P ASX 200 Health Care index fell 13.21% in August as a tough reporting season weighed on sector CSL had its biggest ever one day fall on August 19, down 17% following softer FY25 results and restructure plans Despite the broader...

Compumedics shares surge up to 13% after FDA approval of its Somfit D device Don’t miss out on an options windfall, warns 4D Medical Amplia doses first patient in follow-on pancreatic cancer trial   Brain diagnosis house Compumedics (ASX...

Perversely, Polynovo stands to benefit from a US reimbursement cut for outpatients ASX biotechs had a poor August, but they will Spring into action Race Oncology opens Hong Kong site in “cautious” trial rollout   PolyNovo (ASX:PNV) shares...

Australia’s S&P/ASX 200 rose 3.10% in August and has posted gains of 12.33% so far for CY25 Materials led the gainers up 9.19%, while Healthcare fell 13.21% with CSL having its biggest ever daily fall Rare earths explorer Kaili Resourc...

Good Afternoon and welcome to HotCopper Highlights for Week 32. In this segment we look through the stocks you were watching and discussing the most this week on Australia’s #1 finance website. Let’s get into it, starting with the most view...

ASX slips just 12.3 points, remaining near all-time high Healthcare leads losses as Trump raises tariff spectre Gains in gold and consumer discretionary soften losses   Profit takers stay their hands When markets hit new closing highs, it...

Gold stocks drive gains with index climbing 3.3pc ASX hits new record close at 8843 points Broad market strength with 10 of 11 sectors up Solid gains supported by gold It was another picturesque day of trading on the ASX today, rising st...

Resolution Minerals (ASX:RML) has been the most talked about stock on the HotCopper forums today, and for one big reason: The company fielded an unsolicited $225 million offer to buy its Horse Heaven project. Listen to the HotCopper podc...

Amplia Therapeutics (ASX: ATX) has released new topline data from an ongoing trial of its best-in-class selective FAK inhibitor narmafotinib on advanced pancreatic cancer. The ACCENT clinical trial is investigating the safety, tolerability,...

Nanosonics has hit the double jackpot with its second FDA approval for the year Investor fatigue? Amplia shares tumble after further encouraging pancreatic cancer trial data Duelling parties in the Mayne Group (non) takeover offer stick...

The dangers of biotech investing were on display on Wednesday as Amplia Therapeutics (ASX:ATX), developing a cancer treatment called ACCENT, failed to meet market expectations on the Wednesday session. Listen to the HotCopper podcast for...

With multiple clinical trials and approval applications in train, nuclear medicine superstar Telix Pharmaceuticals (ASX:TLX) is like one of those irritatingly brilliant all-round students. We’re thinking of the straight-A school captain who...

The S&P ASX 200 Health Care index rose 9.05% in July with rotation into the sector gaining momentum  Lumos soared 170% in July after six-year exclusive deal valued at up to US$317 million with PHASE Scientific for distribution of Febri...

 Plenty of biotechs are lodging late in the piece, but without too many ‘dog ate my homework’ excuses Telehealth group looks to post-pandemic recovery   Botanix, Amplia and Vitrafy pass muster with the brokers   Some students hand in thei...

The ASX200 rebounded today and was in the green heading into the close. Investors were buoyant in response to positive inflation data that increased the odds of an interest rate cut in August. Staples, Real Estate and Discretionary were...

Race Oncology (ASX:RAC) has captured the most attention on the HotCopper forums today after successfully – and safely – dosing its first patient with RC220 and RC220 in combination with doxorubicin. Listen to the HotCopper podcast for in...

Telix faces unwanted US regulatory attention – but it’s not alone Amplia raises $25 million, with another $2.5 million to go A home-grown uni biotech innovation shines again   Telix Pharmaceuticals (ASX:TLX) shares this morning slumped up...

ASX slides from record high, down 1.02pc Energy and materials only sectors to lift South32 outperforms production guidance   ASX suffers Liberation Day-sized fall Today was the largest single-day plunge on the ASX since markets went haywi...

ASX biotechs target global cell therapy market, projected to reach ~US$48bn by 2034 Arovella the only ASX-listed biotech delving into CAR iNKT therapies and one of few globally Chimeric aims to ‘break new ground’ in treatment of solid tumo...

It was a tale of two halves for the ASX today, and neither were great  Caution abounds ahead of two major market-moving events this week, including RBA and Trump decisions Utilities stock Origin Energy was a big-cap MVP today, although the...

 Nanosonics has launched tweaked versions of its Trophon medical probe steriliser Amplia shares soar a further 36% on pancreatic cancer promise Dimerix looks to broaden its repertoire     Nanosonics (ASX:NAN) has launched updated iteratio...

ASX hits the breaks, adding just 0.08pc Info tech also contracted, adding 0.54pc compared to more than 1pc earlier in the session Profit taking drives materials, banks lower   3pm slump has ASX yawning to close The ASX 200 pulled back fro...

The ASX 200 Health Care Index fell 1.05% in June and remains the worst performing sector YTD down 6.64% Morgans healthcare analyst Iain Wilkie said June likely saw some tax loss selling before EOFY  Amplia up 300% in June after complete re...

Australia’s S&P/ASX 200 rose 1.4% in June, posting gains of almost 10% for Q2 CY25 The S&P/ASX emerging companies was the only index in the red, down 0.41% Codeifai topped June winners, up 600% after announcing it was acquiring mai...

Highlights Bioxyne outpaces sector peers with performance in cannabis and health products Paradigm Biopharmaceuticals secures convertible note funding for late-stage trial Recce Pharmaceuticals and Botanix turn to debt as eq...

Bioxyne stars with a 720% gain in the 2024-25 year Paradigm shares soar 34% after $41 million convertible note deal Biotechs turn to debt funding The ASX biotech sector’s best EOFY performer has come from left field: the local and Europ...

The bourse’s ‘please explain’ to the cancer drug developer has elicited a lengthy response Last week’s tearaway performer, Amplia will launch a second pancreatic cancer trial The private Myro to launch neuroblastoma trial As any wizened s...

This week’s Bulls N’ Bears ASX Runners of the Week is… Amplia Therapeutics. The biotech beauty might just be onto a fabled golden bullet for hard-to-treat pancreatic cancer.

Highlights Australian shares drift as optimism over a rate cut builds after labour report Financials lift but declines in tech, healthcare and materials limit index gains Amplia Therapeutics and uranium miners drive small-ca...

ASX 200 futures are pointing to a -0.2% slide at open today, after it emerged Donald Trump is pondering a direct attack on Iran – a decision he says he’s going to ruminate on for “the next two weeks” before issuing orders. Listen to the...